Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
NCT05876806
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Cancer
Interventions
DRUG:
Dabrafenib
DRUG:
Trametinib
Sponsor
Se Jun Park